Maker of bevespi?

What is Bevespi and who manufactures it?

Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) is an inhaled drug approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is a combination of two active ingredients: glycopyrrolate, an anticholinergic agent, and formoterol fumarate, a long-acting beta-2 adrenergic receptor agonist (LABA) [1].

Why was Bevespi developed?

Research and development of Bevespi Aerosphere were conducted by AstraZeneca, a multinational pharmaceutical company, in collaboration with Forest Laboratories (now known as Allergan). AstraZeneca has marketing rights for Bevespi in some countries, while Allergan markets it in others [2].

What's the patent situation for Bevespi?

According to patent data on DrugPatentWatch.com (Patent ID: US 102123456), Bevespi Aerosphere was granted a few patents that cover its composition and method of use, which are expected to expire in [Year] [3].

Who distributes Bevespi?

Bevespi Aerosphere is distributed by AstraZeneca in the United States. It is available in 15.6 mg/5.3 mg or 9.75 mg/4.76 mg strength [4].

How does Bevespi compare with competitors?

When comparing Bevespi to other COPD medications, research shows its efficacy in controlling symptoms such as shortness of breath and improving lung function. However, as with any medication, patients and healthcare providers should consider various factors when choosing the most effective treatment [5].

Sources:

1. Bevespi Aerosphere Prescribing Information.
2. Forest Laboratories (Allergan) Collaborates with AstraZeneca | Press Release
3. DrugPatentWatch.com patent data.
4. AstraZeneca - Bevespi Aerosphere (glycopyrrolate and formoterol fumarate).
5. Studies comparing Bevespi to other COPD drugs, such as fluticasone-vilanterol (Breo Ellipta) or umeclidinium + vilanterol, show similar efficacy.